Tigermed
Hangzhou Tigermed Technology Co., Ltd. is a prominent Chinese contract research organization specializing in comprehensive clinical trial services for pharmaceutical research and development. Established with the aim of facilitating medical R&D, Tigermed helps clients mitigate risks and costs associated with bringing new products to market. The company operates 21 subsidiaries across 43 cities worldwide, including major regions in China, North America, Japan, Australia, and Korea, and employs a skilled team of over 900 professionals who adhere to international operational standards. Tigermed offers a range of services, including bioanalytical testing, medical writing, biostatistics analysis, and medical imaging, with a focus on various therapeutic areas such as infections, hematology, cardiovascular diseases, endocrinology, rheumatology, nephrology, and central nervous system disorders. By the end of 2013, Tigermed had successfully provided clinical trial services to over 300 clients and participated in the development of multiple domestic drugs, earning recognition as an "Innovation-type CRO."
26 past transactions
Medical Edge Japan
Acquisition in 2024
ta management and monitoring for all human studies
Bivision
Series A in 2024
Biovision Pharma is a biomedical enterprise focusing on the research and development of targeted radiopharmaceuticals (TRT) integrated with visual diagnosis and treatment.
Marti Farm
Acquisition in 2023
Marti Farm is a contract research organization that provides specialized research and consultancy services to the healthcare, pharmaceutical, biotechnology, food supplement, and cosmetics industries. The company focuses on developing and delivering solutions that enhance health outcomes, collaborating with various businesses to support their research needs. Through its expertise, Marti Farm aims to facilitate the advancement of health-improving innovations across multiple sectors.
Hipower
Series B in 2022
Hipower is a clinical CRO company that helps with drug research and development. After listing them, they reconsidered pharmaceuticals, stem cells, genetic medications, medical gadgets, and other disciplines, such as large-scale variety culture, secondary development of traditional medicine, and research.
LTZ Therapeutics
Seed Round in 2022
LTZ Therapeutics specializes in the development of innovative immunotherapies aimed at treating patients with cancer and other diseases that currently lack effective treatment options. By employing reverse translational science and tumor biology in conjunction with machine learning, the company focuses on creating novel cancer therapies. This approach enables the identification and development of targeted treatments that address unmet clinical needs, ultimately improving patient outcomes in the field of oncology and beyond.
BioInno
Series A in 2021
BioInno is a China-based company that specializes in biopharmaceutical Contract Development and Manufacturing Organization (CDMO) services. It offers process development and Good Manufacturing Practice (GMP) production services tailored for biotechnology and pharmaceutical companies focused on protein, cell therapy, and gene therapy drugs. By facilitating the introduction of these innovative therapies to both the Chinese and global markets, BioInno positions itself as a key partner in the biopharmaceutical industry, helping clients navigate the complexities of drug development and production.
Jisi Yingda
Series B in 2021
Jisi Yingda is a small-molecule anti-cancer drug developer, in the field of small-molecule tumor immune drugs and tumor drug development.
CytoLynx Therapeutics
Funding Round in 2021
CytoLynx Therapeutics is a R&D and commercial platform leveraging Cytovia’s unique technologies and product pipeline.
Adlai Nortye
Series D in 2021
Adlai Nortye Biopharma Co., Ltd. is a clinical-stage biopharmaceutical company based in Hangzhou, China, specializing in the research and development of innovative oncology therapies. Founded in 2004 and formerly known as Sinopep Pharmaceutical Inc., the company focuses on developing cancer treatments and addressing metabolic diseases. Adlai Nortye operates R&D and clinical operation centers in both China and the United States, emphasizing its global approach to drug development. The company has established a robust pipeline featuring over ten drug candidates, including those in various stages of clinical and preclinical development, such as buparlisib, palupiprant, and AN4005. Through collaborations and internal discoveries, Adlai Nortye seeks to advance its goal of providing effective treatment options for patients with a wide range of tumor types.
Gmax Biopharm
Series C in 2021
Gmax Biopharm develops GPCR antibody therapeutics for unmet medical needs in cardiovascular diseases, metabolic disorders, and cancer. Gmax Biopharm develops a proprietary platform with a systemic approach to GPCR MAb generation, screening, and development. Gmax Biopharm enables antibody screening, humanization, and engineering to produce antibody candidates with high drugability and developability.
3D Medicines
Venture Round in 2020
3D Medicines is a biopharmaceutical company focused on personalized cancer treatment. Utilizing individual genetic information, they develop tailored medicines to prevent, diagnose, and treat cancer more effectively and safely than traditional one-size-fits-all approaches. Their primary focus is on immuno-oncology drugs, aiming to prolong survival time and improve quality of life for cancer patients. Currently, all their revenue is generated from operations in China.
Hinova Pharma
Series C in 2020
Hinova Pharmaceuticals Inc. is a drug discovery and development company based in Chengdu, China, with additional branches in Hong Kong, Texas, and Australia. Established in 2013, the company specializes in the research and manufacturing of innovative medicines to address unmet medical needs, particularly in oncology and metabolic diseases. Utilizing advanced technology platforms such as deuterium and PROTAC, Hinova develops both Best-in-class and First-in-class drugs. Its product pipeline includes the HC-1119 androgen receptor antagonist and HC-1102 androgen receptor inhibitors, which target advanced prostate cancer and breast cancer. The company's commitment lies in providing safe, effective, and affordable treatments while retaining global rights and interests in its drug portfolio.
Adlai Nortye
Series C in 2020
Adlai Nortye Biopharma Co., Ltd. is a clinical-stage biopharmaceutical company based in Hangzhou, China, specializing in the research and development of innovative oncology therapies. Founded in 2004 and formerly known as Sinopep Pharmaceutical Inc., the company focuses on developing cancer treatments and addressing metabolic diseases. Adlai Nortye operates R&D and clinical operation centers in both China and the United States, emphasizing its global approach to drug development. The company has established a robust pipeline featuring over ten drug candidates, including those in various stages of clinical and preclinical development, such as buparlisib, palupiprant, and AN4005. Through collaborations and internal discoveries, Adlai Nortye seeks to advance its goal of providing effective treatment options for patients with a wide range of tumor types.
Asieris Pharmaceuticals
Series C in 2020
Asieris Pharmaceuticals Co. Ltd. is a biotechnology company based in Taizhou, China, founded in 2010. The company is dedicated to the research and development of pharmaceutical products aimed at treating tumors and addressing multidrug-resistant infections. By focusing on oncology and infectious diseases, Asieris Pharmaceuticals seeks to develop innovative therapies that meet the medical needs of patients both in China and globally.
CANbridge Pharmaceuticals
Series D in 2020
CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.
EOC Pharma Group
Series C in 2019
EOC Pharma Group is a biopharmaceutical company based in Shanghai, China, founded in 2015. It specializes in the development, manufacturing, and commercialization of innovative oncology products. EOC employs a licensing model to enhance its product pipeline by incorporating molecules from global biopharmaceutical partners into its robust local infrastructure, which includes manufacturing, clinical development, regulatory filing, and commercialization. The company has a diverse pipeline featuring seven novel products, several of which are positioned as potentially first- and best-in-class. EOC has achieved regulatory milestones with four Class I innovative drug approvals and has initiated clinical studies for its leading products. The company operates an 8,000 square meter cGMP manufacturing facility in Taizhou and maintains offices in key locations, including Shanghai, Beijing, Hong Kong, and Los Angeles. With a team of experienced professionals, EOC aims to establish itself as a leader in oncology innovation in China through strategic partnerships and a comprehensive integrated platform.
LaNova Medicines
Angel Round in 2019
LaNova Medicines is a clinical-stage pharmaceutical company specializing in innovative drug research and development, focusing on unmet therapeutic needs in tumor immunity and tumor microenvironment. The company aims to develop 'world's first' and 'best-in-class' potential bio-innovative drugs.
Yaxincheng
Venture Round in 2019
Yaxincheng is a China-based company specializing in medical translation services tailored for the life sciences sector. It offers translation solutions for a variety of documents related to drugs, medical devices, biological products, animal protection, and vaccines. The company facilitates communication across multiple languages, including Chinese, English, French, German, Japanese, Korean, and Spanish, ensuring accurate and culturally relevant translations for research, registration, marketing, training, and management purposes. Yaxincheng aims to support the global healthcare industry by providing essential language services that bridge communication gaps in a highly regulated and technical field.
CMAB BioPharm
Series B in 2018
CMAB BioPharm is a biopharmaceutical service firm based in Suzhou, China, specializing in process development and manufacturing services for biologic products. Established in 2017, the company offers customized development and manufacturing solutions for antibodies and biologics, catering to both domestic and international clients. CMAB BioPharm's services include process development, GMP manufacturing, and the production of aseptic drug products, adhering to stringent quality standards. The firm supports its customers through all stages of drug development, providing comprehensive solutions for preclinical and clinical phases, from initial DNA sequences to commercial production.
Collietech
Corporate Round in 2018
Collietech, established in China, specializes in providing electronic Common Technical Document (eCTD) software and services tailored for the life science industry. Its flagship product is a self-developed eCTD series software, enabling pharmaceutical companies to efficiently register and submit drug product information for international sales.
MED.CIRCLE
Angel Round in 2017
MED.CIRCLE is a medical information service company. It is a service platform that can support many medical academic activities. Their services include medical academic activities and medical device innovation incubation.
Yaxincheng
Angel Round in 2017
Yaxincheng is a China-based company specializing in medical translation services tailored for the life sciences sector. It offers translation solutions for a variety of documents related to drugs, medical devices, biological products, animal protection, and vaccines. The company facilitates communication across multiple languages, including Chinese, English, French, German, Japanese, Korean, and Spanish, ensuring accurate and culturally relevant translations for research, registration, marketing, training, and management purposes. Yaxincheng aims to support the global healthcare industry by providing essential language services that bridge communication gaps in a highly regulated and technical field.
NovaSignal
Series A in 2015
NovaSignal Corporation is a medical device company that specializes in the research, development, and manufacturing of innovative diagnostic and monitoring systems for brain health management. Founded in 2013 and based in Los Angeles, California, with an additional location in Bengaluru, India, the company offers products such as the Lucid robotic system and the Lucid M1 system. These devices employ non-invasive ultrasound technology, robotics, and artificial intelligence to facilitate real-time assessment of cerebral blood flow. NovaSignal's systems are designed to aid in the early detection of conditions such as stroke, trauma, and dementia, providing clinicians with vital information to accurately evaluate brain health. Formerly known as Neural Analytics, Inc., the company rebranded in July 2020 to reflect its focus on advancing neurovascular diagnostics.
DreamCIS
Acquisition in 2015
DreamCIS Inc., established in 2000 and headquartered in Seoul, South Korea, specializes in clinical research services. The company offers a comprehensive range of services including clinical development, biostatistics, data management, pharmacovigilance, medical writing, site startup, clinical monitoring, quality assurance, and regulatory consulting for pharmaceuticals and medical devices. DreamCIS caters to clients such as pharmaceutical companies, bio ventures, and medical device manufacturers, providing professional support throughout the drug development and clinical trial processes. The company is committed to maintaining high-quality standards through scientific and systematic approaches, ensuring ethical practices in its operations.
Yijiayi
Series A in 2015
Yijiayi have treatment methods for cancer patients such as surgery, radiotherapy, and chemotherapy can result in toxic and side effects such as dry mouth, nausea and vomiting, diarrhea, and constipation, as psychological factors such as depression and anxiety, which can affect the patient's appetite and eating habits of nutritional deficiencies in cancer patients.
Frontage Laboratories
Acquisition in 2014
Frontage Holdings Corporation is a contract research organization that offers a comprehensive range of research, analytical, and development services to pharmaceutical, biotechnology, and agrochemical companies. Established in 2018 and headquartered in Exton, Pennsylvania, the company supports drug discovery and development through services such as drug metabolism, pharmacokinetics, safety and toxicology, and bioanalytical testing. Additionally, Frontage provides product development and bioequivalence services that assist generic and consumer health pharmaceutical firms in their regulatory submissions. With operations in North America, including the United States and Canada, as well as in the People's Republic of China and other global markets, Frontage Holdings aims to facilitate the advancement of biopharmaceutical research and development from early stages to late-stage clinical trials. The company is a subsidiary of Hong Kong Tigermed Co., Limited.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.